Prevention of ulcer recurrence after eradication of Helicobacter pylori: A prospective long-term follow-up study

Hulst, R. W. M. Van Der; Rauws, E.A.J.; Koycu, B.; Keller, JJ; Bruno, Mauro; Tijssen, Jan G.P.; Tytgat, G. N. J.

doi:10.1053/gast.1997.v113.pm9322501

Cited by 197 publications

(140 citation statements)

References 12 publications

Supporting

Mentioning

135

Contrasting

Unclassified

Order By: Relevance

“…Afterward, many reports from home and abroad suggested that H. pylori eradication clearly inhibited gastric ulcer from recurring and it accomplished better results than the traditional maintenance treatment using acid reducer. In the case of gastric ulcer, it is also clear that eradicating H. pylori prevents ulcers from recurring as well as the case of duodenal ulcers [45].…”

Section: Prevention Of Ulcer Recurrencementioning

confidence: 99%

“…From the results of a long-term follow-up spent 2.5 years on average and 9.8 years at the longest, they stated that they did not find any recurrences of gastric ulcer from successfully eradicated groups as well as the case of duodenal ulcers [45]. According to the recent meta-analysis of 52 clinical tests conducted around the world, it is effective to eradicate to inhibit both duodenal ulcer and gastric ulcer from recurring [20].…”

Section: Prevention Of Ulcer Recurrencementioning

confidence: 99%

See 1 more Smart Citation

Evidence-based clinical practice guidelines for peptic ulcer disease 2015

et al. 2016

View full text Add to dashboard Cite

The Japanese Society of Gastroenterology (JSGE) revised the evidence-based clinical practice guidelines for peptic ulcer disease in 2014 and has created an English version. The revised guidelines consist of seven items: bleeding gastric and duodenal ulcers, Helicobacter pylori (H. pylori) eradication therapy, non-eradication therapy, drug-induced ulcer, non-H. pylori, non-nonsteroidal anti-inflammatory drug (NSAID) ulcer, surgical treatment, and conservative therapy for perforation and stenosis. Ninety clinical questions (CQs) were developed, and a literature search was performed for the CQs using the Medline, Cochrane, and Igaku Chuo Zasshi databases between 1983 and June 2012. The guideline was developed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. Therapy is initially provided for ulcer complications. Perforation or stenosis is treated with surgery or conservatively. Ulcer bleeding is first treated by endoscopic hemostasis. If it fails, surgery or interventional radiology is chosen. Second, medical therapy is provided. In cases of NSAID-related ulcers, use of NSAIDs is stopped, and anti-ulcer therapy is provided. If NSAID use must continue, the ulcer is treated with a proton pump inhibitor (PPI) or prostaglandin analog. In cases with no NSAID use, H. pylori-positive patients receive eradication and anti-ulcer therapy. If first-line eradication therapy fails, second-line therapy is given. In cases of non-H. pylori, non-NSAID ulcers or H. pyloripositive patients with no indication for eradication therapy, non-eradication therapy is provided. The first choice is PPI therapy, and the second choice is histamine 2-receptor antagonist therapy. After initial therapy, maintenance therapy is provided to prevent ulcer relapse.

show abstract

Section: Prevention Of Ulcer Recurrencementioning

confidence: 99%

Section: Prevention Of Ulcer Recurrencementioning

confidence: 99%

Evidence-based clinical practice guidelines for peptic ulcer disease 2015

et al. 2016

View full text Add to dashboard Cite

show abstract

“…A prospective longterm follow-up study in patients without aspirin or NSAIDs use also showed that none of the H. pylori-eradicated patients with duodenal ulcers (141 patients) and gastric ulcers (45 patients) had an ulcer relapse after a mean follow-up for 9.8 years [Van der Hulst et al 1997]. In a meta-analysis, Hopkins et al found that ulcer recurrence was significantly less common among H. pylori-cured patients as compared to noncured patients (6% vs. 67% for patients with duodenal ulcers; 4% vs. 59% for patients with gastric ulcers) [Hopkins et al 1996].…”

Section: Introductionmentioning

confidence: 99%

“…Eradication of H. pylori has been shown to reduce the recurrence of gastric cancer in patients who received endoscopic mucosal resection (EMR) for early gastric cancer and the recurrence of peptic ulcer in patients with peptic ulcer disease [Ford et al 2006;Uemura et al 1997;Van der Hulst et al 1997;Hopkins et al 1996]. Therefore, eradication of H. pylori as a secondary prophylaxis to prevent recurrence of peptic ulcer disease and gastric cancer has become the standard treatment in clinical practice.…”

Section: Introductionmentioning

confidence: 99%

“…After successful eradication of H. pylori with antibiotics, the risk of ulcer recurrence is reduced dramatically to 5-20% at 1 year [Ford et al 2006;Van der Hulst et al 1997;Hopkins et al 1996;Imperiale et al 1995]. A prospective longterm follow-up study in patients without aspirin or NSAIDs use also showed that none of the H. pylori-eradicated patients with duodenal ulcers (141 patients) and gastric ulcers (45 patients) had an ulcer relapse after a mean follow-up for 9.8 years [Van der Hulst et al 1997].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Review: Eradication of Helicobacter pylori to prevent gastroduodenal diseases: Hitting more than one bird with the same stone

Lee

Liou

et al. 2008

Therap Adv Gastroenterol

View full text Add to dashboard Cite

Abstract:Helicobacter pylori (H. pylori ) are gram-negative bacteria that selectively colonizes the gastric mucosa. The prevalence of H. pylori infection varies from 20 to 50% in industrialized countries to over 80% in developing countries. The infection may persist lifelong without specific treatment. Prolonged infection and inflammation due to bacterial virulence and host genetic factors will lead to chronic gastritis. A certain portion of infected patients then develop more severe pathologies such as peptic ulcer (10-15%), gastric cancer (1%), and mucosaassociated lymphoid tissue lymphoma (50.01%). Although the majority of infected patients remain asymptomatic, much of the evidence has shown that eradication of H. pylori infection can reduce the recurrence of peptic ulcer and benefit a substantial portion of patients with nonulcer dyspepsia. Though controversial in population-based clinical trials, several cost-effectiveness analyses also reveal that H. pylori eradication is cost effective in the primary prevention of gastric cancer. Therefore, the discovery of H. pylori offers the chance to prevent several gastroduodenal diseases by means of their eradication. In other words, gastroenterologists could hit more than one bird with one stone. However, there are concerns regarding application of a 'test and treat' strategy in the general population. In this review, we will focus on current evidence of H. pylori eradication in the primary and secondary prophylaxis of gastric cancer and peptic ulcer disease.

show abstract